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Abstract. Background: Patients with malignant gliomas do
not respond to any current therapy. Epidermal growth factor
receptor (EGFR) controls several oncogenic processes, being
frequently up-regulated in gliomas due to overexpression, gene
amplification and gene mutation. EGFR inhibitors are being
tried in gliomas, yet the molecular determinants of therapeutic
response are unclear. Materials and Methods: EGFR
overexpression, EGFRvIII mutation and EGFR amplification
were determined by immunohistochemistry and chromogenic
in situ hybridization (CISH) in 27 primary glioblastomas
(GBM), 24 anaplastic oligodendrogliomas (AO) and four
anaplastic oligoastrocytomas (AOA). Results: EGFR
overexpression was associated with EGFR amplification, being
found in 48% and 53% GBM, 33% and 40% AO and 75%
and 67% AOA, respectively. EGFRvIII was found in 22%
GBM, 8% AO and was absent in AOA. No association was
observed between EGFR alterations and patient survival.
Conclusion: We characterized, for the first time, EGFR
molecular alterations in Portuguese patients with malignant
glioma and identified a subpopulation of patients presenting
putative biomarkers for EGFR-based therapies.
Gliomas are the most frequent primary central nervous
system (CNS) tumors (1). According to the World Health
Organization (WHO), gliomas are histologically divided
into astrocytic, oligodendroglial and mixed oligoastrocytic
tumors, and are classified into four grades of malignancy (1,
2). Oligodendrogliomas and oligoastrocytomas are stratified
into grade II and grade III (anaplastic) tumors; on the other
hand astrocytomas can be subdivided into grade II, grade
III and grade IV (2). The most malignant form (WHO
grade IV), glioblastoma (GBM), is also the most frequent
glioma subtype (1, 2). GBMs can be divided into primary
glioblastomas, which arise de novo and are molecularly
characterized by epidermal growth factor receptor (EGFR)
overexpression/amplification, and secondary glioblastomas,
which are derived from lower-grade astrocytomas and are
characterized by TP53 mutations (3). The prognosis of
patients with GBM is very poor, with survival usually less
than twelve months (1, 4). Recently, the introduction of
temozolomide-based chemotherapy in concomitancy with
radiotherapy, led to increased GBM patient survival (15
months) (4). However, these results are far from being
satisfactory and there are still patients that do not respond
favorably to any described therapy. Therefore, it is
necessary to understand the molecular features of gliomas
in order to identify novel and effective therapeutic targets.
Receptor protein tyrosine kinases (RTKs) are major
regulators of cell growth signaling and their importance in
tumorigenesis and progression has been extensively
investigated (5). Epidermal growth factor receptor
(EGFR)/HER1 is a member of the class I epidermal growth
factor family, which also includes HER2, HER3 and HER4.
EGFR is a transmembrane glycoprotein that is stimulated
by growth factors, namely the transforming growth factor-·
(TGF-·) and EGF ligands, which bind to the extracellular
domain of the receptor (6). Ligand binding to EGFR
activates the receptor through dimerization leading to signal
transduction and activation of downstream intracellular
pathways, mainly RAS/RAF/MAPK, PI3K/AKT and
STATs, that regulate cellular proliferation, differentiation,
migration and survival (5). Several mechanisms of aberrant
EGFR activation have been reported in cancer cells, namely
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overexpression of the ligand EGF and of the receptor,
EGFR gene amplification and activating mutations.
Moreover, dysregulated EGFR activation is known to act
oncogenically, stimulating the growth and spread of cancer
cells (5). Therefore, due to the paramount role of EGFR in
tumorigenesis, several therapeutic strategies are being
developed to target and inhibit signalling via the receptor
(7-9). Monoclonal antibodies (mAbs) bind to the
extracellular domain of EGFR inhibiting this region and
blocking ligand binding. Cetuximab (IMC-C225, Erbitux)
and Panitumumab (ABX-EGF, Vectibix) are EGFR-
binding mAbs currently approved for the treatment of
colorectal cancer (10). Alternatively, EGFR tyrosine kinase
inhibitors (TKIs) bind to the intracellular tyrosine kinase
domain, blocking kinase activity as well as the downstream
signaling. Gefitinib (ZD1839, Iressa) and erlotinib (OSI-
774, Tarceva), are EGFR TKIs already approved for non-
small cell lung cancer (NSCLC) patients (11).
In high-grade gliomas, EGFR is the most frequently
amplified oncogene, being present in 40% of primary GBM
and poorly characterized in anaplastic astrocytomas and
anaplastic oligodendrogliomas (AO) (12-14). Importantly,
EGFR gene amplification is known to be associated with
protein overexpression in gliomas (2). Additionally, in about
half of GBM cases with EGFR amplification, the event is
coupled with EGFR gene mutations, with EGFRvIII (also
known as ¢EGFR and del2-7EGFR) the most common in
GBM (2, 15, 16). This EGFR mutant oncoprotein lacks a
portion of the extracellular ligand-binding domain as a
result of a genomic deletion involving exons 2 to 7, resulting
in a mutant protein unable to bind EGFR ligands, yet
constitutively activated in a ligand-independent manner
leading to overproliferation of cancer cells (6, 17). EGFR
represents an attractive therapeutic target in malignant
gliomas and even though there are no anti-EGFR agents
approved for glioma treatment at present, there are several
ongoing clinical trials evaluating the efficacy of mAbs and
TKIs in gliomas (7, 18, 19).
In the present study, we aimed to characterize the most
common mechanisms (EGFR overexpression, gene
amplification and EGFRvIII mutation) involved in EGFR
activation in a Portuguese cohort of high-grade (astrocytic,
oligodendroglial and mixed) gliomas and to identify the
subset of patients that would potentially benefit from
EGFR-targeted therapies.
Materials and Methods
Patients and tumor samples. Sixty-two formalin-fixed, paraffin-
embedded samples of sporadic gliomas from 55 patients were
retrieved from the Department of Pathology of the S. João
Hospital, Porto and S. Marcos Hospital, Braga, Portugal, as well
as the available patients’ clinical data, as described elsewhere (20).
Tumor samples were classified according to the WHO classification
of CNS tumors (2): as 31 primary GBM (WHO grade IV), 26 AO
(WHO grade III), one oligodendroglioma (O) (WHO grade II)
and four anaplastic oligoastrocytomas (AOA) (WHO grade III)
(Tables I and II). Twenty-seven (49.1%) patients were male and 28
(50.9%) were female; the mean age was 56.1 years (range 27-79
years) (Tables I and II).
EGFR and EGFRvIII immunohistochemistry. Formalin-fixed, paraffin-
embedded tissue sections were used in the immunohistochemical
analysis. Previously documented mouse monoclonal anti-EGFR
(clone 31G7, 1:100; Zymed® Laboratories Inc., South San Francisco,
CA, USA) and mouse monoclonal anti-EGFRvIII antibody (clone
G100, 1:100; Zymed®Laboratories Inc.) were used as primary
antibodies (18, 21). Anti-EGFRvIII antibody specifically recognizes
EGFRvIII and does not cross-react with the wild-type form (18).
Immunohistochemistry for EGFR was performed as described
elsewhere (22). Briefly, after deparaffinization, sections were
rehydrated and washed. Antigen retrieval was achieved by 20 min
incubation at 37˚C with a bacterial protease extracted from
Streptomyces griseus (Sigma-Aldrich Co., St. Louis, MO, USA).
Endogenous peroxidase activity was blocked using 3% H2O2 in
methanol for 10 min and samples were then incubated with Ultra V
block (Lab Vision Corporation, Fremont, CA, USA) for 10 min at
room temperature (RT). After incubation with primary antibody,
overnight at RT, the secondary biotinylated goat anti-polyvalent
antibody (Lab Vision Corporation) was applied for 10 min followed
by 10 min incubation with Streptavidine Peroxidase (Lab Vision
Corporation) at RT.
For the EGFRvIII reaction, sections were deparaffinized,
incubated in 0.3% H2O2 in methanol for 30 min to block
endogenous peroxidase activity and rehydrated. Antigen retrieval
was achieved by microwaving sections in 10 mM citrate buffer (pH
6.0) three times for 5 min at 700 W. Sections were then incubated
with Ultra V block (Lab Vision Corporation) for 20 min at RT.
After incubation with primary antibody overnight at 4˚C, the
biotinylated “universal” secondary antibody (Vector Laboratories,
Burlingame, CA, USA) was applied for 30 min followed by R.T.U.
Vectastain®Elite ABC reagent (Vector Laboratories) incubation
for 45 min at 37˚C. Both EGFR and EGFRvIII sections were
incubated with the chromogen 3,3’-diaminobenzidine (DAB)
(Ultravision Detection System Anti-polyvalent, HRP/DAB; DAKO
Corporation, Carpentaria, CA, USA), for 10 min at RT.
Haematoxylin counterstaining was performed in a Leica Auto
Stainer XL (Meyer Instruments Inc., Houston, TX, USA).
A specimen of human skin and a human glioblastoma with
documented expression of EGFRvIII were used as positive controls for
EGFR and EGFRvIII, respectively (22,23). Neoplastic cells with
membranous and/or cytoplasmic intense immunoreactivity were
considered positively stained. Both the distribution and intensity of the
immunoreactivity were semi-quantitatively scored as follows: _ (0%),
+ (<10%), ++ (10-50%), and +++ (>50%). Samples with scores
(_) and (+) were considered negative, and those with scores (++) and
(+++) were considered positive as described elsewhere (22,23).
Chromogenic in situ hybridization (CISH). The presence of EGFR
gene amplification was assessed with CISH using Spot-Light
amplification probes for EGFR (Zymed®Laboratories Inc.). CISH
was performed using Spot-Light CISH Polymer Detection Kit
(Zymed®Laboratories Inc.) in accordance with the manufacturer’s
protocol, and as described elsewhere (22). Amplification was defined
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as more than 5 signals per nucleus in more than 50% of cancer cells,
or when large gene copy clusters were seen. Signals were evaluated
at x400 and x600 and at least 60 morphologically unequivocal
neoplastic cells were counted for the presence of the gene probe
signals. CISH hybridizations were evaluated in a blinded manner, by
two independent observers, on a multi-headed microscope.
Statistical analysis. Statistical analysis was performed using SPSS
for Windows (version 14.0; SPSS Inc., Chicago, IL, USA). The
correlation between categorical variables was calculated for
statistical significance using Pearson’s chi-square test and the
threshold for significance was p≤0.05.
Follow-up information was available for 40 out of 55 patients,
with follow-up periods ranging from 1 to 93 months (median 11
months, mean 16 months). Survival duration was defined as the
time between diagnosis and death. Associations among EGFR
expression, amplification, EGFRvIII expression and patients’ age
with patients’ survival were assessed using Cox proportional
hazards regression analyses.
Results
EGFR protein overexpression. EGFR immunohistochemical
analysis was performed on 62 glioma samples from 55
patients. Results are summarized on Table I and Table II.
The EGFR neoplastic staining was membranous and/or
cytoplasmic, without immunoreactivity of endothelial
tumor cells (Figure 1 A and B). EGFR overexpression
(2+/3+) was detected in 24 of 55 tumors (44%). A high
percentage of positive cases was found in all histological
types of gliomas analyzed, namely, 48% (13/27) of GBM
(Table I, Figure 1A), 33% (8/24) of AO and 75% (3/4) of
AOA (Table II, Figure 1B).
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Table II. Results of EGFR analysis in anaplastic oligodendrogliomas and
oligoastrocytomas.
Case Age (years)/ IHC - CISH - IHC -
No. gender EGFR EGFR EGFRvIII
amplification
Anaplastic oligodendrogliomas
60 65/M ++ Not Ampl _
62 47/F + Not Ampl _
64 65/F + NC _
66 50/M + Not Ampl _
68 36/F _ Not Ampl _
70 60/F _ NC _
71 53/M ++ Not Ampl _
72 65/M +++ Ampl ++
73 47/M _ Not Ampl _
76 70/F _ Not Ampl _
81 64/F + NC _
83 54/M + Not Ampl _
110 44/M _ Not Ampl _
110† 44/M _ Not Ampl _
112 42/F + Ampl _
115 40/M ++ Not Ampl _
116 51/M _ Ampl +++
118 64/F ++ Ampl _
119 68/F + Ampl _
163 51/M +++ Ampl _
168‡ 36/M + ND ND
168† 36/M _ Not Ampl +
170 73/M _ Not Ampl _
172 45/M +++ ND ND
172† 45/M +++ Ampl _
202 65/F +++ Ampl _
259 52/F _ NC _
Anaplastic oligoastrocytomas
63 46/F + Not Ampl _
203 36/F ++ NC _
205 33/M ++ Ampl _
206 55/F +++ Ampl +
ND, not determined; NC, not conclusive; Ampl, amplified; Not Ampl,
not amplified; †, recurrence; ‡, oligodendroglioma grade II.
Table I. Results of EGFR analysis in glioblastomas.
Case Age (years)/ IHC - CISH - IHC -
No. gender EGFR EGFR EGFRvIII
amplification
12 27/F + Not Ampl _
13 54/F +++ Ampl _
14 41/M _ Not Ampl _
19 61/F _ Not Ampl _
20 77/M +++ Ampl _
21 67/F _ Not Ampl _
22 50/F + Ampl ++
23 73/M + Not Ampl _
24 57/M +++ Ampl _
24† 57/M +++ Ampl ++
26 28/M +++ NC _
29 51/F +++ Ampl _
30 69/M _ NC _
30† 69/M _ ND _
32 53/M +++ NC ++
32† 53/M ++ ND +
33 59/F +++ Ampl +
36 56/F +++ Ampl +++
37 66/M _ NC _
38 68/F _ ND _
40 60/F _ NC _
41 58/F _ Not Ampl _
42 60/M +++ Ampl _
43 73/M +++ Ampl _
45 66/F ++ Not Ampl +++
48 54/M +++ Not Ampl _
48† 54/M + Not Ampl _
94 66/F + NC _
96 79/M + Ampl _
97 72/M _ Not Ampl _
231 62/F ++ NC +++
ND, not determined; NC, not conclusive; Ampl, amplified; Not Ampl,
not amplified; †, recurrence.
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Figure 1. EGFR cytoplasmic/membranous immunohistochemistry expression in GBM (A, x200) and AO (B, x400). EGFR amplification revealed by high
nuclear signaling in GBM (C, x100) and AO (D, x100; inset, x600). EGFRvIII cytoplasmic/membranous immunohistochemistry expression in GBM (E,
x200) and AO (F, x400).
EGFR amplification. CISH analysis was possible in 54
tumors and was conclusive in 42 (78%) of the cases (Tables
I and II). The pattern of EGFR signals observed using
CISH was compatible with double minute amplification
(Figure 1C and D). Overall, EGFR gene amplification was
detected in 20 (48%) high-grade gliomas. Specifically,
EGFR gene amplification was observed in 53% of GBM
(10/19) (Table I, Figure 1C), 40% of AO (8/20) (Table II,
Figure 1D) and 67% of AOA (2/3) (Table II). Of the 20
gliomas with EGFR amplification, 15 (75%) exhibited
EGFR overexpression (p=0.001). All recurrent cases with
available CISH analysis for both primary and recurrent
samples, namely two GBM (cases 24 and 48) and one AO
(case 110), showed the same EGFR amplification status.
EGFRvIII protein overexpression. EGFRvIII expression
analysis was performed in 60 samples of 55 gliomas and
results are summarized in Table I and Table II. EGFRvIII
staining was predominantly cytoplasmic and was observed
only in neoplastic cells, not in endothelial tumor cells
(Figure 1E and F).
EGFRvIII overexpression was observed in 22% of GBM
(6/27) (Table I, Figure 1E), 8% of AO (2/24) (Table II, Figure
1F) and was absent in AOA (0/4) (Table II). In GBM, all but
one sample with EGFRvIII overexpression also exhibited
EGFR overexpression (Table I, p=0.114). Similarly, with the
exception of one case, all informative samples with EGFRvIII
overexpression also showed EGFR gene amplification (Table
I, p=0.596). Both AO cases with EGFRvIII overexpression
depicted EGFR gene amplification, (Table II, p=0.068) one
of them also with EGFR overexpression (Table II, p=0.602).
Clinical significance of EGFR overexpression, EGFR
amplification and EGFRvIII overexpression. Association
between patient age and EGFR overexpression was assessed
for glioma, GBM and AO patients (data not shown). EGFR
overexpression in GBM patients tended (p=0.082) to occur
in younger patients. Multivariate analysis (Cox proportional
hazards) was used to determine the association between
patient age, EGFR overexpression, EGFR amplification or
EGFRvIII overexpression and overall survival for GBM and
AO. The median age of patients was calculated for GBM
(60 years) and AO (51 years) and these values were used to
split patients into younger and older groups. Survival time
was calculated after one year for GBM patients and after
five years for AO patients. No correlation was found
between EGFR overexpression, EGFR amplification, or
EGFRvIII overexpression and overall survival of GBM and
AO patients (Table III). EGFR overexpression showed a
tendency (p=0.054, Table III) for being associated with
shorter survival in AO patients. There was a significant
correlation (p=0.014, Table III) between being older and
better survival in AO patients.
Discussion
In this study, we characterized, for the first time, the
presence of EGFR alterations in a series of high grade
gliomas from Portuguese patients. We studied a total of 31
GBM and observed that the frequency of GBM presenting
EGFR overexpression (48%), EGFR amplification (53%)
and EGFRvIII overexpression (22%) were in line with the
published literature (24-26). Similarly to several studies a
positive correlation (p=0.012) was found between EGFR
overexpression and gene amplification in GBM (14, 18, 24,
27). Additionally, all but one GBM with EGFRvIII
overexpression presented gene amplification, which is also
in agreement with previous studies (24, 25). It was
previously reported that older patients with GBM have
higher rates of EGFR overexpression and amplification (24,
28). We found no statistical differences between patient age
and EGFR overexpression, EGFR gene amplification, or
EGFRvIII overexpression in the same cases.
EGFR activation status in anaplastic oligodendrogliomas has
been less frequently reported (13, 27, 29, 30). We analyzed 24
cases and observed EGFR overexpression in 33%, EGFR
amplification in 40% and EGFRvIII mutation in 8% of
anaplastic oligodendrogliomas. EGFR overexpression tended
to correlate with gene amplification (p=0.094). Other authors
described EGFR amplification in anaplastic oligodendrogliomas
and frequencies varied from 0-42.5% (13, 27, 31). A possible
reason for this discrepancy is the distinct methodologies used.
Regarding EGFRvIII expression, results are few and
contradictory. Wikstrand and colleagues analyzed 5 anaplastic
oligodendrogliomas and described a frequency of 20% of
EGFRvIII expression (30); however, in another study from the
same group EGFRvIII was not found to be expressed in 25
anaplastic oligodendrogliomas (29).
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Table III. Multivariate analysis for the effect of EGFR overexpression,
EGFR amplification, EGFRvIII overexpression and age on survival of
GBM and AO patients.
Variable Hazard ratio p-value
(95% confidence interval)
GBM (1-year survival)
EGFR overexpression 3.655 (0.731-18.277) 0.114
EGFR amplification 1.073 (0.167-6.885) 0.941
EGFRvIII overexpression 0.732 (0.131-4.095) 0.723
Median age (<60 or ≥60 years) 1.222 (0.204-7.333) 0.826
AO (5-year survival)
EGFR overexpression 36.927 (0.942-1447.576) 0.054
EGFR amplification 0.112 (0.007-1.710) 0.116
EGFRvIII overexpression NS
Median age (<51 or ≥51 years) 0.065 (0.007-0.570) 0.014
NS: Insufficient data for statistical evaluation.
The influence of EGFR overexpression, EGFR gene
amplification and EGFRvIII overexpression in patient
prognosis has been highly controversial for gliomas (24, 25,
28, 32-37). To clarify this issue, we performed a multivariate
analysis and found no association between these EGFR
alterations and patients’ overall survival in our cohort.
EGFR is becoming an important therapeutic target, with
some anti-EGFR drugs already being used in clinical
practice and several novel EGFR inhibitors under
development (38). Among the two major approaches, using
EGFR-TKIs and mAbs, the former seems to be more
suitable for gliomas due to their low molecular weight
potentially being better at overcoming the blood_brain
barrier (39). In NSCLC, the presence of activating
mutations in the EGFR kinase domain was associated with
selective EGFR-TKI sensitivity, allowing the selection of
patients with a higher probability of clinical response to
gefitinib and erlotinib (11). However, these mutations have
never been found in glioma cell lines (11), or in glioma
patients (11, 40, 41). Recently, Lee and colleagues reported
EGFR activation in GBM due to missense mutations in the
EGFR extracellular domain (42). They reported that
transformed cells with the EGFR ectodomain mutations
had increased sensitivity to erlotinib; however studying
DNA samples from a previous clinical trial, these authors
were unable to associate EGFR ectodomain mutations with
clinical responses to EGFR TKI inhibitors (42).
The few clinical trials with gefitinib and erlotinib in
gliomas included a small number of patients and variable
molecular markers, insufficient for conclusive results
regarding patients’ response and EGFR molecular status.
Rich and colleagues, in a phase II trial, described a
monotherapy study with gefitinib in GBM patients and
found neither objective tumor response nor association
between EGFR expression, EGFR amplification, or
EGFRvIII expression and gefitinib response (43).
Franceschi and colleagues’ recent phase II trial investigated
the role of gefitinib in patients with high-grade gliomas and
reported an 18% stable disease rate without any correlation
of EGFR expression or gene status and tumor response
(44). Vogelbaum et al. described a monotherapy with
erlotinib in patients with recurrent GBM and found 25%
with stable disease and 25% with partial response rates;
although EGFR amplification was observed in about 50% of
tumors, it was not associated with erlotinib response (45).
In a phase II study with erlotinib in recurrent GBM,
Cloughesy et al. described a 33% stable disease rate and
EGFR expression associated with a slight tendency for
better patient outcome (46). Haas-Kogan et al. reported that
the presence of EGFR overexpression and gene
amplification, associated with low levels of activated Akt,
were associated with response to erlotinib, suggesting that
these molecular alterations could be predictive markers for
EGFR-TKI sensitivity in gliomas (18). Mellinghoff et al.
described that coexpression of EGFRvIII and phosphatase
and tensin homolog (PTEN) (RTK downstream negative
regulator) was associated with a better response to gefitinib
and erlotinib in recurrent GBM (19). In general, results with
erlotinib seem to be more promising than with gefitinib,
possibly due to its targeting of both EGFRvIII mutant and
wild-type EGFR (39).
There have also been clinical trials involving EGFR-
targeted mAbs in gliomas (9, 47). A phase I/II clinical trial
using the EGFR mAb h-R3 in malignant glioma enrolled 29
patients with an objective response in 37.9% and stable
disease in 41.4% of the cases (47). Another phase I/II trial
using cetuximab in GBM is ongoing (9). There are several in
vitro and in vivo studies reporting EGFR-targeted mAbs
effects in glioma. Recently, Johns et al. studied the efficacy
of two EGFR-specific mAbs (mAbs 806 and 528) against
glioma cell line-derived xenografts expressing EGFR and
EGFRvIII and reported that their efficacy was dependent
on EGFR overexpression and receptor activation status
(48). Currently, considerable efforts are being made to
design anti-EGFRvIII strategies, such as mAbs and
vaccines, since this mutated form constitutes a tumor-
specific target that is not present in normal cells.
In conclusion, in the present study, we found that a high
percentage of GBM and AO exhibited EGFR
overexpression and amplification, as did a significant
proportion of GBM and a small proportion of AO
expressing EGFRvIII. Our results represent the first step
for the identification of Portuguese glioma patients who
could respond to specific therapies targeting EGFR.
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